Due to health issues, this site is no longer maintained and will be shut down shortly.

NVNO enVVeno Medical Corporation

enVVeno Medical, formerly Hancock Jaffe Laboratories, specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValve“, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraft“, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.

$4.80  -0.10 (-2.04%)
As of 03/24/2023 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  
IPO date:  05/31/2018
Outstanding shares:  9,472,000
Average volume:  22,032
Market cap:   $46,412,800
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy